Business Context and Reporting Period
Company: Oramed Pharmaceuticals Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: September 30, 2025
Event: Execution of the first tranche of a warrant repurchase agreement with Scilex Holding Company.
Key Financial Metrics
This filing reports a specific transaction rather than comprehensive financial statements. Key transaction metrics include:
- Transaction Type: Repurchase of warrants held by Oramed to purchase Scilex Holding Company common stock.
- Tranche 1 Execution: Repurchase of 3,130,000 warrants for $13,000,000.
- Total Agreement Value: $27,000,000 for 6,500,000 warrants.
- Remaining Obligation: Option to repurchase 3,370,000 warrants for $14,000,000 by December 31, 2025.
Note: The filing text does not provide clear values for Oramed's revenue, profit, cash flow, margins, debt, or liquidity.
Material Changes
The material change reported is the partial execution of the Option Agreement for the Repurchase of Warrants entered into on July 22, 2025. On September 30, 2025, Scilex exercised its option to repurchase the first tranche of warrants, resulting in a cash inflow of $13,000,000 to Oramed.
Outlook and Contingencies
- Future Transaction: Scilex retains the option to repurchase the remaining 3,370,000 warrants for $14,000,000 on or before December 31, 2025.
- Contingency: The completion of the second tranche is subject to the terms and conditions of the Option Agreement.
Investor Verification Checklist
- Verify the cash impact of the $13,000,000 received from the first tranche on Oramed's current liquidity position.
- Confirm the terms and conditions in the Option Agreement that govern the second tranche repurchase deadline of December 31, 2025.
- Review the relationship between Oramed and Scilex Holding Company to understand the strategic rationale for the warrant repurchase.